Sangamo Therapeutics, Inc. (SGMO)

Market Cap	188.91M
Revenue (ttm)	57.80M
Net Income (ttm)	-97.94M
Shares Out	224.71M
EPS (ttm)	-0.49
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	3,603,591
Open	0.880
Previous Close	0.870
Day's Range	0.827 - 0.880
52-Week Range	0.300 - 3.180
Beta	1.50
Analysts	Buy
Price Target	5.17 (+514.96%)
Earnings Date	Mar 17, 2025

About SGMO

Sangamo Therapeutics, Inc., a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company’s clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of imm...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Apr 6, 2000
• Employees: 405
• Stock Exchange: NASDAQ
• Ticker Symbol: SGMO
• Website: https://www.sangamo.com

Financial Performance

In 2024, Sangamo Therapeutics's revenue was $57.80 million, a decrease of -67.20% compared to the previous year's $176.23 million. Losses were -$97.94 million, -62.01% less than in 2023.

Analyst Forecast

According to 6 analysts, the average rating for SGMO stock is "Buy." The 12-month stock price forecast is $5.17, which is an increase of 514.96% from the latest price.

Price Target

$5.17

(514.96% upside)

Analyst Consensus: Buy